The Minister of Health Examined the Production Facilities of Darnitsa and Noted the Important Role of the Pharmaceutical Industry in Strengthening of the Country’s National Security

Viktor Liashko, the Head of the Ministry of Health of Ukraine, visited the plant of Darnitsa Pharmaceutical Company. The Minister saw for himself the high level of efficiency and quality of Darnitsa’s production facilities, which fully meets European standards.

“Coordinated cooperation with the leaders of the pharmaceutical industry is the key to the national security amidst the COVID-19 pandemic and to the successful response to other challenges to the country’s healthcare system. The state is interested in developing long-term and systematic cooperation with Ukrainian pharmaceutical companies. The development of the national pharmaceutical production is one of the goals of the National Economic Strategy for the period up to 2030, which was approved by the Government in March 2021,” said the Minister of Health Viktor Liashko.

In 2021, Darnitsa produced 181 million packs of drugs, which is an unprecedented quantity for the country. This high figure once again put Darnitsa in first place in terms of volumes of drug production in Ukraine. In addition, thanks to the productive work of the R&D department and the use of innovative technologies, last year the company launched 22 new brands of medicines.

Darnitsa is ranked among TOP-1000 pharmaceutical companies of the world. In one minute of the working day, the plant produces 62 ampoules of medicines, 484 tablets and 14 vials of drops. Citramon-Darnitsa tablets have been recognized as a remedy No. 1 for headaches in Ukraine and are the only domestic drug that is among the top five leaders of pharmacy sales. In general, every seventh pack of drugs in Ukrainian pharmacies is manufactured by Darnitsa Pharmaceutical Company.

“In the current context, a powerful and innovative pharmaceutical industry is not only an important element of healthcare, but also an integral part of the country’s national security,” said Dmytro Shymkiv, the Chairman of the Board of Directors of Darnitsa Group, “the Ukrainian market is the priority for us, and therefore Darnitsa focuses on creating effective, safe and affordable medicines for Ukrainians”.

At the same time, Darnitsa has enough production capacity to meet the needs of not only the domestic market. The company currently supplies its medicines to 15 countries in the EU, the CIS, the Middle East and Eastern Asia. The annual growth rate of the company’s exports is about 30%. An additional factor in the attractiveness of Darnitsa’s products on the international market is the Good Manufacturing Practice (GMP) certification, which the company has been successfully receiving since 2002.

Darnitsa is incessantly working on the implementation of the latest technologies at all levels and stages of the production – from digitalization of document management to automation of production and logistics facilities. Both Darnitsa and the Ministry of Health are mutually interested in the development of the domestic pharmaceutical industry, which is the basis for further cooperation. Among the possible areas of collaboration in the future are the development of biotechnology, the introduction of innovative research methods, as well as the development of effective and safe means of combating coronavirus strains and overcoming COVID-19 in general.

“The pharmaceutical industry with its constant needs for production optimization and sophisticated technologies for development and research has always been at the forefront of Ukraine’s innovative development. Borrowing of our work by the state is a perfectly natural process, and we will be happy to translate it into an official format. For example, with the support of the Ministry of Health and the country’s leadership in general, Darnitsa can help to create a full-fledged anticoronavirus hub in Ukraine, which will provide vaccines, as well as preventive and therapeutic tools to the country and Eastern Europe,” Dmytro Shymkiv noted.

Background information

Darnitsa Pharmaceutical Company PrJSC was established in 1930. Since 1998, Darnitsa has been the leader in Ukraine in terms of production of drugs by volume. The strategic areas of the portfolio development are cardiology, neurology, pain management. During 2015-2021, Darnitsa launched more than 70 pharmaceutical brands.